KINAXIS
Kinaxis® (TSX:KXS), the leading supply chain management platform, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2023. The call will be hosted on Thursday, February 29 at 8:30 a.m. Eastern Time by John Sicard, Chief Executive Officer, and Blaine Fitzgerald, Chief Financial Officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year-end after the close of markets on Wednesday, February 28, 2024.
CONFERENCE CALL DETAILS
DATE: |
Thursday, February 29, 2024 |
||
TIME: |
8:30 a.m. Eastern Time |
||
CALL REGISTRATION: |
|||
WEBCAST: |
https://events.q4inc.com/attendee/409673001 (available for three months) |
||
REPLAY: |
(800)-770-2030 or (609) 800-9909 |
||
|
Available through March 14, 2024 |
||
|
Reference number: 91416 |
Advance call registration
Investors and participants must register in advance for the call. After registering, instructions on how to join the call will automatically be emailed, including dial-in information as well as a unique pincode. At the time of the call, registered participants will dial in using the numbers from the confirmation email, and upon entering their unique pincode, will be entered directly into the conference. It is recommended that you register for the call at least 15 minutes prior to the start time.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201774521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa and Transcard Collaborate to Deliver Advanced Embedded Working Capital Solutions in Freight & Logistics4.11.2025 14:00:00 CET | Press release
New partnership expands the reach of embedded finance for the freight sector, powering operational agility for WebCargo by Freightos ® users Visa and Transcard today announced the launch of a next-generation embedded finance platform, designed to power payments and working capital solutions in the freight and logistics industry. As a part of their joint effort, Visa and Transcard are also collaborating on agentic initiatives for the B2B segment. This alliance puts embedded credit and working capital solutions in the hands of freight forwarders and airline carriers on WebCargo by Freightos (Nasdaq: CRGO), a leading digital booking and payments platform in the freight industry. By combining Visa’s global expertise in commercial solutions with Transcard’s leading-edge payment orchestration technology, WebCargo users can now gain access to flexible credit terms, seamless onboarding and automated reconciliation for air cargo transactions. The solution, built on Visa’s virtual card infrastru
Esri Supports IUCN Global Initiative for Nature-Based Education4.11.2025 14:00:00 CET | Press release
New Collaborative GeoPortal Will Help Deliver Data, Maps, Educational Resources, and ArcGIS Technology for Students, Teachers, and Conservationists Around the World At the 2025 IUCN World Conservation Congress, Esri, the global leader in geographic information system (GIS) technology, announced a joint initiative with the International Union for Conservation of Nature (IUCN) and its Commission on Education and Communication to expand access to data, maps, and GIS technology in support of Nature-based Education (NbE) worldwide. Esri is making a $10 million in-kind donation to enable the development of a new NbE geoportal that will allow students, teachers, and IUCN conservationists around the world to understand and explore our planet through maps and the science of geography, collaborate on critical conservation solutions, and develop critical technical skills for future careers in conservation. This new initiative, now in the pilot phase of consultation and design, will support IUCN’s
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release
New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release
First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release
Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom